Search Results
Your search for Blood matches 4802 pages
Showing 2651 - 2700FDA Expands Approval of Brentuximab Vedotin for First-Line Treatment of Stage III or IV Classical Hodgkin Lymphoma in Combination With Chemotherapy
On March 20, the U.S. Food and Drug Administration (FDA) approved brentuximab vedotin (Adcetris) to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma in combination with chemotherapy. “Today’s approval represents an improvement in the initial...
Conquer Cancer Foundation Recognizes 70 Young Oncology Researchers’ Findings With Merit Awards
ASCO’s Conquer Cancer Foundation is pleased to announce the recipients of its Merit Awards in gastrointestinal cancers, clinical immuno-oncology, genitourinary cancers, and cancer survivorship. The following 70 researchers— oncology fellows and trainees honored for the quality and scientific merit...
Triplet Therapy Poses a Triple Threat to BRAF-Mutated Colorectal Cancers
Triplet therapy that inhibits the BRAF, MEK, and epidermal growth factor receptor (EGFR) pathways appears promising in BRAF-mutated colorectal cancer, a malignancy that typically does not respond to BRAF inhibition alone. Early results from the BEACON CRC study showed a 48% response rate and an...
Targetable Immune Biology Found in Some Patients With Early-Stage Prostate Cancer
Although immunotherapy has improved outcomes across a growing number of cancers, its success in unselected cases of prostate cancer has been limited. According to data presented at the 2018 ASCO-SITC Clinical Immuno-Oncology Symposium, however, investigators have identified a group of patients with ...
AACR 2018: Prior Chemotherapies May Impair Pediatric Patients’ Ability to Develop Effective CAR T Cells
Pediatric patients with solid tumors may have poor quality T cells compared to patients with leukemia, and certain chemotherapies were detrimental to the T cells and their potential to become chimeric antigen receptor (CAR) T cells, according to data presented during a media preview for the...
AACR 2018: Chlamydia Infection May Be Associated With Increased Risk of Ovarian Cancer
An antibody that is present in the blood of women previously infected with the sexually transmitted infection chlamydia is associated with a doubling in ovarian cancer risk, according to data presented during a media preview for the 2018 American Association for Cancer Research (AACR) Annual...
Patients With AML Have Reduced Risk of Early Mortality at NCI-Designated Cancer Centers
Researchers at the University of California (UC), Davis, have shown that patients with acute myeloid leukemia (AML) who received their care at a National Cancer Institute (NCI) cancer center in California had a dramatically reduced risk of early mortality. Using data from the California Cancer...
The Anesthesia Era: 1845–1875
The text and photograph on this page are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photo below is from the volume titled “The Anesthesia Era: 1845–1875.” The photograph...
CAR T-Cell Therapy in Refractory B-Cell Lymphomas
As reported at the 2017 American Society of Hematology Annual Meeting & Exposition and in The New England Journal of Medicine, Stephen J. Schuster, MD, of the Perelman School of Medicine at the University of Pennsylvania, and colleagues found that chimeric antigen receptor (CAR) T-cell...
A River Runs Through the Life of a Leukemia Specialist
GUEST EDITOR Dr. Abraham is the Director of the Breast Oncology Program at Taussig Cancer Institute, and Professor of Medicine, Lerner College of Medicine, Cleveland Clinic. MATT KALAYCIO, MD Affiliation: Cleveland Clinic Taussig Cancer InstituteOn balancing priorities: “As an oncologist in...
FDA Accepts NDA, Grants Priority Review for Ivosidenib in Relapsed or Refractory IDH1-Mutated AML
On February 15, the U.S. Food and Drug Administration (FDA) accepted a new drug application (NDA) for ivosidenib (AG-120) for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase 1 (IDH1) mutation. The NDA was granted Priority Review...
Answers to Hematology Expert Review Questions
GUEST EDITORS: Dr. Abutalib is Assistant Director, Hematology and Hematopoietic Cell Transplantation Director, Hematopoietic Cell Transplant Apheresis Service, Cancer Treatment Centers of America, Zion, Illinois, Editor-in-Chief, Advances in Cell & Gene Therapy. Dr. Medeiros is Professor and...
The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Abutalib and Medeiros explore the recently updated World Health Organization (WHO) classification of hematopoietic and lymphoid tissue...
Cabozantinib in Advanced Renal Cell Carcinoma
ON DECEMBER 19, 2017, cabozantinib (Cabometyx) was granted regular approval for the treatment of advanced renal cell carcinoma.1,2 Cabozantinib was initially granted approval in 2016 for the treatment of patients with advanced renal cell carcinoma who had received prior antiangiogenic therapy. The...
Bosutinib in Newly Diagnosed Chronic-Phase Philadelphia Chromosome–Positive Chronic Myeloid Leukemia
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On December 19, 2017, bosutinib (Bosulif) was granted...
Interventions to Address Sexual Problems in People With Cancer: ASCO Clinical Practice Guideline Adaptation of CCO Guideline
AS REPORTED in the Journal of Clinical Oncology by Jeanne Carter, PhD, of Memorial Sloan Kettering Cancer Center, and colleagues, ASCO has issued a clinical practice guideline adaptation of the Cancer Care Ontario (CCO) guideline on interventions to address sexual problems in people with cancer.1 ...
Lutetium Lu-177 Dotatate in Gastroenteropancreatic Neuroendocrine Tumors
On January 26, 2018, the radiolabeled somatostatin analog lutetium Lu-177 dotatate (Lutathera) was approved for the treatment of somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors, in adults.1,2 Supporting...
Rutgers Cancer Institute Welcomes New Oncology Leadership
RUTGERS CANCER INSTITUTE of New Jersey at the University Hospital in Newark has named several new oncology leaders, further enhancing the facility’s expertise and ability to deliver National Cancer Institute (NCI)-designated comprehensive cancer center services to the greater Essex County region....
Apalutamide, Enzalutamide Improve Metastasis-Free Survival in Nonmetastatic Castrate-Resistant Prostate Cancer
IN TWO SEPARATE TRIALS presented at the 2018 Genitourinary Cancers Symposium, apalutamide and enzalutamide (Xtandi), respectively, reduced the risk of metastasis and prolonged metastasis-free survival in men with high-risk nonmetastatic castrate-resistant prostate cancer. In the SPARTAN trial,1,2...
Circulating Tumor DNA and Pseudoprogression in Metastatic Melanoma Treated with Anti–PD-1 Antibodies
In a study reported in JAMA Oncology, Lee et al found that measurement of circulating tumor DNA (ctDNA) can help distinguish between pseudoprogression (radiologic progression prior to response) and true progression in patients with metastatic melanoma receiving anti–programmed cell death ...
E. John Wherry, PhD, Awarded SU2C Funding to Lead Investigation of Gynecologic Cancer Therapies
E. John Wherry, PhD, a cancer and immunology researcher at the Perelman School of Medicine at the University of Pennsylvania and one of the most highly cited investigators in his field, has been awarded a “Convergence 2.0” research grant by Stand Up to Cancer (SU2C) to investigate immune system...
Cognitive Decline Prevalent Among Elderly Patients With Hematologic Cancers
A sizable percentage of elderly patients with blood-related cancers such as leukemia and multiple myeloma are apt to show signs of diminished cognitive functioning—a decline that may impact their survival—a new study by investigators at Dana-Farber Cancer Institute and Brigham and...
Bevacizumab in Recurrent Glioblastoma
On December 5, 2017, bevacizumab (Avastin) was granted regular approval for the treatment of recurrent glioblastoma in adults.1 Bevacizumab was granted accelerated approval in May 2009 for use in treating patients with glioblastoma who had disease progression on prior therapy. Supporting Efficacy...
Study Finds Colorectal Cancer Screenings Vary Widely Throughout the United States
A study examining prevalence estimates of colorectal cancer screening at the county level in the United States has found that the country is far behind reaching the goal of screening 80% of adults aged 50 and older for colorectal cancer by 2018, which is supported by the National Colorectal Cancer...
Genomic Analyses Highlight Need for Precision Therapies That Target Pediatric Cancers
Researchers have determined that children and adults with cancer often have different mutated genes driving their disease, which suggests they would likely benefit from different therapies. The finding, from a collaborative study led by St. Jude Children’s Research Hospital and published by...
Nut Consumption in Patients With Stage III Colon Cancer
People with stage III colon cancer who regularly eat nuts are at significantly lower risk of cancer recurrence and mortality than those who don’t, according to findings published by Fadelu et al in the Journal of Clinical Oncology. Findings The study followed 826 participants in the CALGB...
Data Favoring Maintenance Therapy in Older Patients With AML Accumulate
The use of maintenance therapy in older patients with acute myeloid leukemia (AML) is theoretically sensible, but its clinical value remains uncertain. The phase III HOVON97 randomized study demonstrated that maintenance therapy with the hypomethylating agent azacitidine may improve disease-free...
Serum Bone Biomarkers in Early Breast Cancer and Risk of Bone Metastasis
In a study reported in the Journal of the National Cancer Institute, Brown et al found that the serum bone biomarkers P1NP, CTX, and 1-CTP showed good prognostic ability for bone metastasis in patients in the phase III AZURE (BIG01/04) trial of adjuvant zoledronic acid in early breast cancer....
FDA Accepts NDA, Grants Priority Review for Ivosidenib in Relapsed or Refractory IDH1-Mutated AML
On February 15, the U.S. Food and Drug Administration (FDA) accepted a new drug application (NDA) for ivosidenib (AG-120) for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase 1 (IDH1) mutation. The NDA was granted Priority Review...
Combining Ultrasound Imaging With Alpha-Fetoprotein Test May Boost Detection of Hepatocellular Carcinoma
Combining ultrasound imaging with a blood test for high alpha fetoprotein levels may improve detection of early-stage liver cancer by as much as 40%, researchers at UT Southwestern’s Simmons Cancer Center found. Their findings were presented by Tzartzeva et al in Gastroenterology....
Combined Medical and Psychological Approach May Help Couples Reclaim Intimacy After Prostate Cancer Treatment
“To what extent do treatments for prostate cancer impact sexual functioning? To a great extent,” Christian Nelson, PhD, Chief, Psychiatry Service, Memorial Sloan Kettering Cancer Center, New York, told participants at the 11th Annual Oncofertility Consortium Conference in Chicago.1 Most men with...
EXPERT POINT OF VIEW: Douglas Corley, MD, PhD and Nancy Baxter, MD
In a discussion of the study, Douglas Corley, MD, PhD, of the Division of Research at Kaiser Permanente, San Francisco Medical Center, California, said it remains unclear whether blood tests can improve the early detection of cancer, though such an approach would be welcomed. “We are getting closer ...
Use of Circulating Tumor Cells to Detect Colorectal Cancer and Adenomas
Circulating tumor cells (CTCs) in the blood had an accuracy of up to 88% in detecting colorectal cancer and 84% in identifying adenomas, in a study from Taiwan presented at the 2018 Gastrointestinal Cancers Symposium by Wen-Sy Tsai, MD, of Linkou Chang Gung Memorial Hospital in Taipei.1 “The study ...
Releasing Follicular Lymphoma From the Curse of Frankenstein
In the December 10, 2017, issue of The ASCO Post, I authored an article in which I raised the possibility of curing follicular lymphoma without the dreaded chemotherapy. Clearly, no good deed goes unpunished: My good friend and The ASCO Post’s editor Jim Armitage, MD, challenged me to defend that...
FDA Grants Priority Review to Lorlatinib in ALK-Positive NSCLC
On February 12, the U.S. Food and Drug Administration (FDA) accepted and granted Priority Review to Pfizer’s new drug application for lorlatinib. The Prescription Drug User Fee Act goal date for a decision by the FDA is in August 2018. Lorlatinib is an investigational, anaplastic lymphoma...
Adjuvant Zoledronic Acid in Early Breast Cancer: Is 5 Years Better?
THE PHASE III SUCCESS A trial, presented at the 2017 San Antonio Breast Cancer Symposium, found no benefit for extending the use of intravenous zoledronic acid from 2 years to 5 years.1 “At this time point, our study showed no difference in disease-free survival or overall survival between 5 years ...
Novel Agent Appears Active in Advanced or Aggressive Systemic Mastocytosis
THE INVESTIGATIONAL agent BLU-285 (avapritinib) has shown significant activity in patients with advanced or aggressive forms of systemic mastocytosis, a rare blood disorder that originates in mast cells, according to the findings of a phase I trial reported at the 2017 American Society of...
Daratumumab Shows Efficacy in Amyloid Light-Chain Amyloidosis
DARATUMUMAB (DARZALEX) may be an effective treatment for systemic amyloid light-chain (AL) amyloidosis, according to phase II studies reported at the 2017 American Society of Hematology (ASH) Annual Meeting & Exposition.1,2 While the cohorts were small and the arms uncontrolled, the findings...
Scientific Statement From the American Heart Association Examines Intersection of Breast Cancer and Cardiovascular Disease
Patients with breast cancer may be at an increased risk of cardiovascular diseases, including heart failure, and may benefit from a treatment approach that weighs the benefits of specific therapies against potential damage to the heart, according to a new scientific statement from the American...
2018 GU CANCERS SYMPOSIUM: Adding Immunotherapy to Standard Treatment Slows Growth of Advanced Kidney Cancer—With Fewer Side Effects
In a phase III clinical trial of patients with previously untreated metastatic renal cell cancer combining the immunotherapy atezolizumab (Tecentriq) with the targeted therapy bevacizumab (Avastin) delayed cancer growth by about 3 months longer than sunitinib, another targeted therapy. The benefit...
2018 GU CANCERS SYMPOSIUM: New Model Predicts Survival for People With Bladder Cancer Receiving Immunotherapy
Researchers have developed a model to predict overall survival for people with advanced urothelial cancers treated with the immune checkpoint inhibitor atezolizumab (Tecentriq). The model, which is based on six clinical factors, may help inform treatment decisions for use of atezolizumab in these...
2018 GU CANCERS SYMPOSIUM: Apalutamide Delays Prostate Cancer Metastases by More Than 2 Years
Findings from the phase III placebo-controlled SPARTAN trial suggest that apalutamide is an effective treatment for men with nonmetastatic castration-resistant prostate cancer who are at high risk for developing metastatic disease and for whom no approved treatments exist. Men who received...
Combined Aerobic-Resistance Exercise Intervention in Overweight/Obese Survivors of Breast Cancer
In a study reported in the Journal of Clinical Oncology, Dieli-Conwright et al found that an aerobic and resistance intervention reduced metabolic syndrome factors and sarcopenic obesity among sedentary, overweight, or obese women with breast cancer. Study Details In the study, 100 women from...
The Toxicity of Time
The ASCO Post is pleased to reproduce installments of the “Art of Oncology” as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Daratumumab in Previously Treated Multiple Myeloma
On June 16, 2017, daratumumab -(Darzalex) was approved for use in combination with pomalidomide (Pomalyst) and dexamethasone for treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide (Revlimid) and a proteasome inhibitor.1,2 Supporting...
Enasidenib in IDH2-Mutant Relapsed or Refractory Acute Myeloid Leukemia
On August 1, 2017, the IDH2 inhibitor enasidenib (Idhifa) was granted regular approval for treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by a U.S. Food and Drug Administration (FDA)-approved...
Alexis A. Thompson, MD, MPH, Appointed 2018 ASH President
Alexis A. Thompson, MD, MPH, an expert in sickle cell disease and thalassemia, will serve as President of the American Society of Hematology (ASH) for a 1-year term through December 2018. Dr. Thompson is Head of the Hematology Section of the Division of Hematology Oncology Transplantation and...
Making Personalized Medicine a Reality for More Patients With Cancer
This past September, Olivier Elemento, PhD, Associate Director of the Institute for Computational Biomedicine and Director of the Laboratory of Cancer Systems Biology at Weill Cornell Medicine in New York, was named Director of Weill Cornell’s Englander Institute for Precision Medicine. In this...
Updated Analysis of ELIANA Trial Shows Longer-Term Durable Remissions With Tisagenlecleucel in Children, Young Adults With Relapsed/Refractory ALL
Updated results from the ELIANA clinical trial of tisagenlecleucel (Kymriah), formerly CTL019, in relapsed or refractory pediatric and young adult patients with B-cell acute lymphoblastic leukemia (ALL) have been published by Maude et al in The New England Journal of Medicine. New data include...
Obese Men May Have Higher Risk for Biochemical Recurrence Following Radical Prostatectomy
Among men with prostate cancer who underwent radical prostatectomy, those who were obese had a higher risk of biochemical recurrence, according to data presented at the American Association for Cancer Research (AACR) Special Conference on Obesity and Cancer: Mechanisms Underlying Etiology and...
